ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

BMS and BioMotiv launch first biotech firm

by Lisa M. Jarvis
February 7, 2020 | APPEARED IN VOLUME 98, ISSUE 6

 

Bristol-Myers Squibb and the drug-development accelerator BioMotiv have launched Anteros Pharmaceuticals, a biotech firm developing drugs for fibrosis and inflammatory diseases. The start-up, which is based on technology developed at Yale University, is the first company to come out of a pact forged last fall between BMS and BioMotiv, which aims to advance discoveries made at research institutions. Bringing a molecule from the academic licensing stage to the clinic can cost $5 million to $7 million, a cost that the partners will share, BioMotiv CEO Satish Jindal says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment